Piper Sandler Boosts Replimune Group (NASDAQ:REPL) Price Target to $22.00

Replimune Group (NASDAQ:REPL) had its target price hoisted by Piper Sandler from $14.00 to $22.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

REPL has been the subject of several other research reports. HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.75.

Replimune Group Stock Up 0.6%

Shares of Replimune Group stock opened at $9.69 on Monday. Replimune Group has a 1 year low of $4.93 and a 1 year high of $17.00. The business has a 50-day moving average of $8.34 and a two-hundred day moving average of $11.05. The company has a market capitalization of $746.97 million, a P/E ratio of -3.16 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.25) earnings per share. As a group, equities analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Activity

In related news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the sale, the director now owns 1,405,071 shares of the company’s stock, valued at approximately $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 25,105 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $202,346.30. Following the sale, the chief executive officer now owns 343,576 shares in the company, valued at $2,769,222.56. The trade was a 6.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 over the last ninety days. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently made changes to their positions in the stock. Boxer Capital Management LLC acquired a new position in Replimune Group during the fourth quarter worth $21,754,000. Tang Capital Management LLC grew its position in shares of Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after acquiring an additional 1,500,000 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock worth $132,761,000 after purchasing an additional 1,083,633 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of Replimune Group during the 4th quarter worth about $11,504,000. Finally, RTW Investments LP raised its holdings in shares of Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after purchasing an additional 931,223 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.